Matsumaru Yuji, Ishikawa Eiichi, Yamamoto Tetsuya, Matsumura Akira
Division for Stroke, Department of Neurosurgery, Faculty of Medicine, University of Tsukuba.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba.
Neurol Med Chir (Tokyo). 2017 Jun 15;57(6):253-260. doi: 10.2176/nmc.ra.2017-0027. Epub 2017 May 1.
The efficacy of mechanical thrombectomy with stent retrievers for emergent large vessel occlusion has been proved by randomized trials. Mechanical thrombectomy is increasingly being adopted in Japan since stent retrievers were first approved in 2014. An urgent clinical task is to offer structured systems of care to provide this treatment in a timely fashion to all patients with emergent large vessel occlusion. Treatment with flow-diverting stents is currently a preferred treatment option worldwide for large and giant unruptured aneurysms. Initial studies reported high rates of complete aneurysm occlusion, even in large and giant aneurysms, without delayed aneurysmal recanalization and/or growth. The Pipeline Embolic Device is a flow diverter recently approved in Japan for the treatment of large and giant wide-neck unruptured aneurysms in the internal carotid artery, from the petrous to superior hypophyseal segments. Carotid artery stenting is the preferred treatment approach for carotid stenosis in Japan, whereas it remains an alternative for carotid endarterectomy in Europe and the United States. Carotid artery stenting with embolic protection and plaque imaging is effective in achieving favorable outcomes. The design and conclusions of a randomized trial of unruptured brain arteriovenous malformations (ARUBA) trial, which compared medical management alone and medical management with interventional therapy in patients with an unruptured arteriovenous brain malformation, are controversial. However, the annual bleeding rate (2.2%) of the medical management group obtained from this study is worthy of consideration when deciding treatment strategy.
随机试验已证实,使用支架取栓器进行机械取栓治疗急性大血管闭塞具有疗效。自2014年支架取栓器首次获批以来,机械取栓在日本的应用越来越广泛。一项紧迫的临床任务是提供结构化的护理系统,以便及时为所有急性大血管闭塞患者提供这种治疗。目前,对于大型和巨大型未破裂动脉瘤,使用血流导向支架治疗是全球范围内的首选治疗方案。初步研究报告称,即使是大型和巨大型动脉瘤,完全动脉瘤闭塞率也很高,且无动脉瘤延迟再通和/或生长。Pipeline栓塞装置是一种最近在日本获批用于治疗颈内动脉从岩段至垂体上段的大型和巨大型宽颈未破裂动脉瘤的血流导向装置。在日本,颈动脉支架置入术是治疗颈动脉狭窄的首选方法,而在欧洲和美国,它仍是颈动脉内膜切除术的替代方法。带有栓塞保护和斑块成像的颈动脉支架置入术能有效取得良好疗效。一项针对未破裂脑动静脉畸形(ARUBA)的随机试验,比较了未破裂脑动静脉畸形患者单纯药物治疗和药物治疗联合介入治疗的效果,其设计和结论存在争议。然而,在决定治疗策略时,本研究中药物治疗组的年出血率(2.2%)值得考虑。